Illegal Ayurvedic Medicines Unit Raided In Vasai By FDA, Medicines Seized

Palghar: A firm in Vasai in Palghar district was raided by the Food and Drug Administration and Ayurvedic medicines manufactured without licence and other items worth Rs 1 crore were seized, an official said on Friday.

The raid was carried out by the Intelligence Branch of FDA, Mumbai on a tip off on Thursday, he said.

“It held a manufacturing licence for Panchkula in Haryana but was carrying out manufacturing activities in its firm in Navghar in Vasai. Further investigation is under progress and suitable legal action would be taken against the said manufacturer after completion of investigation,” the official said.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices